Literature DB >> 7688386

Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226.

G G Freund1, D T Kulas, R A Mooney.   

Abstract

Insulin receptors and insulin-like growth factor-1 (IGF-1) receptors are present in circulating human B lymphocytes (B cells) and certain B cell malignancies, but no function has been attributed to either receptor. We report a human myeloma cell line, RPMI 8226, that exhibits insulin and IGF-1-dependent receptor and substrate tyrosine phosphorylation as well as hormone-responsive cellular metabolism. Competitive hormone-binding analysis revealed that the cell line expressed approximately 4 x 10(3) high affinity insulin binding sites and 1.1 x 10(4) high affinity IGF-1 binding sites per cell. The Kd of the insulin-binding sites for insulin was 0.32 nM. The Kd of high affinity IGF-1 binding sites for IGF-1 was 0.89 nM. Insulin receptor autophosphorylation was maximum at 200 nM as was tyrosine phosphorylation of the 180-kDa cytosolic receptor substrate. Insulin-dependent activation of phosphatidylinositol 3-kinase paralleled receptor phosphorylation. In contrast, IGF-1 produced its maximum effects at 200 nM for receptor phosphorylation and 20 nM for substrate phosphorylation and PI 3-kinase activation. In growth synchronized cells, IGF-1 and insulin at 200 nM increased DNA synthesis by 122 +/- 18% and 101 +/- 27%, respectively. IGF-1 increased DNA synthesis 88 +/- 21% at 2 nM and the effect of insulin at 2 nM was 34 +/- 12%. Flux through the glycolytic pathway was also increased by insulin and IGF-1. At 200 and 2 nM, insulin increased production of lactate by 33 +/- 9% and 19 +/- 11%, respectively. IGF-1 increased lactate production 47 +/- 3% and 23 +/- 3% at identical hormone concentrations. Finally, in two additional myeloma cell lines, U266 (human) and Ag8.653 (mouse), insulin and IGF-1 increased tyrosine phosphorylation of receptor beta-subunit (95 kDa), the prominent 180-kDa substrate (pp185), and several other substrates. Thus, functional insulin and IGF-1 receptors are present in myeloma cell lines. Through these receptors, insulin and IGF-1 regulate mitogenesis and glucose metabolism, and may be important in potentiating plasma cell malignancy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688386

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Authors:  Teru Hideshima; Laurence Catley; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Constantine Mitsiades; Klaus Podar; Nikhil C Munshi; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma.

Authors:  Yong-Geun Kwak; Chang H Song; Ho K Yi; Pyoung H Hwang; Jong-Suk Kim; Kyung S Lee; Yong C Lee
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

4.  Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2.

Authors:  Devin T Worster; Tobias Schmelzle; Nicole L Solimini; Eric S Lightcap; Bjorn Millard; Gordon B Mills; Joan S Brugge; John G Albeck
Journal:  Sci Signal       Date:  2012-03-06       Impact factor: 8.192

Review 5.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

6.  Lactic acidosis in a patient with multiple myeloma.

Authors:  B A Mizock; J N Glass
Journal:  West J Med       Date:  1994-10

7.  JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.

Authors:  Tanyel Kiziltepe; Teru Hideshima; Kenji Ishitsuka; Enrique M Ocio; Noopur Raje; Laurence Catley; Chun-Qi Li; Laura J Trudel; Hiroshi Yasui; Sonia Vallet; Jeffery L Kutok; Dharminder Chauhan; Constantine S Mitsiades; Joseph E Saavedra; Gerald N Wogan; Larry K Keefer; Paul J Shami; Kenneth C Anderson
Journal:  Blood       Date:  2007-03-23       Impact factor: 22.113

8.  Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation.

Authors:  A C Sprynski; D Hose; A Kassambara; L Vincent; M Jourdan; J F Rossi; H Goldschmidt; B Klein
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

9.  The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Authors:  Anne Catherine Sprynski; Dirk Hose; Laurent Caillot; Thierry Réme; John D Shaughnessy; Bart Barlogie; Anja Seckinger; Jérôme Moreaux; Michael Hundemer; Michel Jourdan; Tobias Meissner; Anna Jauch; Karène Mahtouk; Alboukadel Kassambara; Uta Bertsch; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2009-02-18       Impact factor: 22.113

10.  B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.

Authors:  Raymond S Douglas; Vibharavi Naik; Catherine J Hwang; Nikoo F Afifiyan; Andrew G Gianoukakis; Daniel Sand; Shweta Kamat; Terry J Smith
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.